A Beginner's Guide to the Sliding Window Algorithm with JavaScript Learn the basics of the Sliding Window algorithm in ...
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
On Nov. 18, 2026, Recursion shares climbed after regulators aligned on its lead familial adenomatous polyposis trial, though ...
This pharmaceutical-development technology company continues to demonstrate that its testing platform has real potential.
Good morning, everyone, and thank you for joining Recursion's Third Quarter Earnings Call. We're hosting earnings live from the CGA-IGC Annual Meeting in Denver. Today, we'll share the new FAP data ...
Kiah Treece is a former attorney, small business owner and personal finance coach with extensive experience in real estate and financing. Her focus is on demystifying debt to help consumers and ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Together AI builds an agentic compiler to try and bring recursive self improvement capabilities to open source models.
A new sampling algorithm, the open-closed mod-minimizer, reduces the space required for genomic indexes by up to 18 percent ...
Researchers have developed a quasilinear-time subtree prune and regraft algorithm for median quartet tree search that ...
RXRX is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.10 since the market last closed. This is a 3.72% ...